A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)
NCT06780150
·
clinicaltrials.gov ↗
RECRUITING
Status
842
Enrollment
INDUSTRY
Sponsor class
Conditions
Multiple Sclerosis
Interventions
DRUG:
Ocrelizumab
Sponsor
Hoffmann-La Roche